Musella Foundation awards 9 grants!
Our largest grant was a payment of $250,000 towards a $1 Million pledge we made to open the compassionate use program for the experimental drug ONC-201 in the USA, and to track the patients so we learn from every patient's experiences. We are now saving for the next payment, due at the end of this year, as well as another $2 million to open the program in the rest of the world!
Posted on: 06/24/2019
Musella Foundation awards 9 grants!
Hewlett, NY 6/24/2019 - The Musella Foundation is pleased to announce that we have awarded 9 grants in the total amount of $495,000. These funds were raised by the National Walk To End Brain Tumors (WalkToEndBrainTumors.org), donations to our organization and through a collaboration with the Cure Starts Now and the Michael Mosier Defeat DIPG Foundation! A big thanks to all those who contributed and to our volunteers!
- $250,000 to Oncoceutics,Inc, as second payment of a $1 million grant, for the project "Onc-201 for DIPG and High Grade Gliomas with the H3 K27M mutation!" This is in collaboration with the Cure Starts Now and the Michael Mosier Defeat DIPG Foundation!
- $100,000 to Dr Manmeet Ahluwalia at the Cleveland Clinic for the project titled: "Blood based biomarkers and tissue genomics, transciptome and tumor mutational burden to assess correlation to responses seen in A Randomized Phase 2 Open Label Study of Nivolumab plus standard dose Bevacizumab versus Nivolumab plus low dose Bevacizumab in Recurrent Glioblastoma (GBM)"
- $35,000 to Dr Eric Wong at Beth Israel Deaconess Medical Center for the project titled: "Computer Modeling of Tumor Treating Fields in the FORWARD Trial "
- $35,000 to Dr Michael Olin at the University of Minnesota for the project titled: "Targeting multiple immune checkpoints with a single checkpoint inhibitor: implications for immunotherapy against CNS cancer"
- $25,000 to Dr Shawn Carbonell at Oncosynergy for the project titled: "Development of Novel Antibodies for Evaluating Dose-Response Relationship in a Phase I Trial of OS2966 in the Treatment of Recurrent High-Grade Glioma"
- $20,000 to Dr Vitanza at Seattle Children's for the project: "Optimal therapeutic timing of locoregional B7-H3 CAR T cell immunotherapy and radiation for children with DIPG " This grant is from our DIPG All-In-Initiative fund.
- $10,000 to Clinwiki, Inc to continue the project "ClinWiki Search Implementation" This project will make it easier for patients to find clinical trials, and hopefully increase clinical trial participation! This is the second grant for this project.
- $10,000 to the Central Brain Tumor Registry of the United States for the project titled: "Provision of the most current population-based statistical information for all primary brain and other central nervous system (CNS) tumors in the United States" This is our annual grant to help support this important ongoing project.
- $10,000 to Dr Madan Kwatra of Duke University for the project "Heterogeneity of EGFRvIII-positive glioblastoma and their sensitivity to AZD9291 (Osimertinib)"
About the Musella Foundation
The Musella Foundation For Brain Tumor Research & Information, Inc is a 501(c)3 non- profit organization dedicated to speeding up the search for the cure of brain tumors, as well as helping families deal with the diagnosis of brain cancer, by funding innovative brain tumor research, education, advocacy, emotional and financial support for families that are dealing with brain tumors and organizing the brain tumor community to work together as an army to fight the disease.
Contact: Al Musella, DPM
President Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
Click HERE to return to brain tumor news headlines